Dishman Carbogen
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Dishman Carbogen Amcis Limited (DCAL) is positioned for moderate growth, supported by management's optimistic outlook and strategic initiatives. Key developments include a robust pipeline of late-phase ADC projects and a focus on high-margin oncology products, which are expected to drive revenue growth of approximately 15% in FY27 and FY28. Management's strategy to enhance capacity utilization and expand into new geographies aligns with Vista's forecast of stable margins and fair valuation. The company's commitment to achieving an EBITDA margin of 25% by FY28 reflects its focus on operational efficiency. However, challenges such as high effective tax rates and project-based revenue uncertainty may temper short-term performance. The broader industry context, characterized by increasing demand for contract manufacturing and regulatory shifts, supports DCAL's growth trajectory. Over the next 12-24 months, key opportunities include leveraging India's cost advantages and expanding its client base among small to mid-sized biotech firms. Conversely, watchpoints include potential raw material supply constraints and competitive pricing pressures. Overall, while the outlook remains cautiously optimistic, the investment recommendation reflects a balanced view of growth potential against inherent risks
Why We Like This Stock
- Strong pipeline of late-phase ADC projects expected to drive revenue growth of approximately 15% in FY27 and FY28
- Strategic investments in capacity expansion and a focus on high-margin oncology products enhance competitive positioning
- Management's goal of achieving a 25% EBITDA margin by FY28 reflects a commitment to operational efficiency
Things To Watch Out For
- High effective tax rates and project-based revenue uncertainty may impact short-term financial performance
- Competitive pricing pressures within the fragmented CDMO market could challenge margin stability
- Potential raw material supply constraints may hinder production capabilities and affect growth
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 2,616 | 2,712 | 2,932 | 2,935 | 3,112 |
| Profit Before Tax (Cr.) | -118 | 36 | 109 | 47 | 66 |
| PBT Margin | -4.5% | 1.3% | 371.8% | 1.6% | 2.1% |
| Net Profit (Cr.) | -174 | -47 | 99 | 44 | 62 |
| Earnings Per Share | -11.1 | -3.0 | 6.3 | 2.8 | 3.9 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
Dishman Carbogen Amcis Limited provides contract research and manufacturing services for the pharmaceutical and healthcare industries worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments. It offers cholesterol and vitamin D analogs; generic active pharmaceutical ingredients for diagnostics, ophthalmic treatments, laxatives, organophosphate antidotes; ammonium, phosphonium; quats, phosphoranes, and wittig reagents; cholesterol and lanolin-related products; sterile injectables; and softgel formulations, as well as hand and body wash, sanitisers, and antiseptics. The company was founded in 1983 and is headquartered in Ahmedabad, India. Dishman Carbogen Amcis Limited is a subsidiary of Adimans Technologies LLP.